AQR Capital Management
RPRX

AQR Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

AQR Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-47,097
Closed -$337K – 2384
2015
Q2 		$337K Sell
47,097
-35,803
-43% -$279K ﹤0.01% 1935
2015
Q1 		$713K Buy
82,900
+58,700
+243% +$525K ﹤0.01% 1562
2014
Q4 		$242K Buy
24,200
+8,441
+54% +$72K ﹤0.01% 2297
2014
Q3 		$156K Sell
15,759
-5,300
-25% -$78.5K ﹤0.01% 2396
2014
Q2 		$364K Sell
21,059
-7,100
-25% -$116K ﹤0.01% 2127
2014
Q1 		$500K Hold
28,159
– – ﹤0.01% 2042
2013
Q4 		$515K Sell
28,159
-7,200
-20% -$136K ﹤0.01% 2050
2013
Q3 		$948K Sell
35,359
-305,200
-90% -$6.54M ﹤0.01% 1684
2013
Q2 		$6.28M Buy
+340,559
New +$6.01M 0.02% 774

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

AQR Capital Management's RPRX Position: Q3 2015 in Review

AQR Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 47,097 shares — an estimated $337K sold.

AQR Capital Management first reported a position in RPRX in Q2 2013 and held it in 9 quarters. The position peaked at $6.28M in Q2 2013. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

  • AQR Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • AQR Capital Management sold 47,097 Repros Therapeutics Inc. shares in Q3 2015, an estimated $337K.
  • AQR Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 9 quarters.
  • AQR Capital Management's Repros Therapeutics Inc. position peaked at $6.28M in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on AQR Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.